



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2024.

Rs. In Lakhs						
STANDALONE						
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended	
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	160.99	257.29	245.08	518.88	930.77
	Other Income	156.93	403.48	606.56	953.51	1,684.69
	Total income	317.92	660.77	851.64	1,472.39	2,615.46
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	486.58	520.34	432.04	1,475.88	1,307.02
	d) Finance costs	0.79	1.56	3.54	4.66	12.85
	e) Depreciation and amortisation expense	153.35	145.51	160.09	447.50	499.18
	f) R & D Expenses	826.49	908.96	618.85	2,194.43	1,621.28
	g) Other Expenses	177.90	191.59	114.00	550.89	409.23
	Total expenses	1,645.11	1,767.96	1,328.52	4,673.36	3,849.56
3	Profit before exceptional items & Tax (1-2)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(1,234.10)
4	Exceptional Items	-	-	-	-	745.66
5	Profit before Tax (3-4)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(488.44)
6	Tax Expenses					
	a) Current tax	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(488.44)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(0.45)	(0.45)	4.75	(1.35)	14.24
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(0.45)	(0.45)	4.75	(1.35)	14.24
9	Total Comprehensive Income for the period (7+8)	(1,327.64)	(1,107.64)	(472.13)	(3,202.32)	(474.20)
10	Paid-up equity share capital	2,180.74	2,180.74	2,180.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity					
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	(0.61)	(0.51)	(0.22)	(1.47)	(0.22)
	b) Diluted	(0.61)	(0.51)	(0.22)	(1.47)	(0.22)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)
						(annualised)



CONSOLIDATED							
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	160.99	257.29	245.08	518.88	930.77	1,169.29
	Other Income	163.05	403.56	606.56	967.44	1,684.69	2,113.00
	Total Income	324.04	660.85	851.64	1,486.32	2,615.46	3,282.29
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	486.58	520.34	579.37	1,475.88	1,552.27	1,898.75
	d) Finance costs	0.79	1.56	3.54	4.66	12.85	15.84
	e) Depreciation and amortisation expense	153.35	145.51	160.29	447.50	499.38	650.22
	f) R & D Expenses	3,413.32	4,758.49	4,162.19	10,663.68	8,690.55	11,442.72
	g) Other Expenses	181.66	199.33	122.74	574.61	459.63	628.29
	Total expenses	4,235.70	5,625.23	5,028.13	13,166.33	11,214.68	14,635.82
3	Profit before exceptional items , Tax (1-2)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(8,599.22)	(11,353.53)
4	Exceptional Items	-	-	-	-	745.66	745.66
5	Profit before Tax (3-4)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(7,853.56)	(10,607.87)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(7,853.56)	(10,507.63)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
9	Total Comprehensive Income for the period (7+ 8)	(3,912.11)	(4,964.83)	(4,171.74)	(11,681.36)	(7,839.32)	(10,513.63)
10	Paid-up equity share capital Face Value of the Share	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00
11	Other Equity	-	-	-	-	-	24,823.32
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)
	b) Diluted	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 24, 2025 . The results for the quarter ended December 31, 2024 has been reviewed by our statutory auditors

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc

4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The Company has allotted 7,26,91,239 equity shares amounting to Rs.39,980.18 lakhs through rights issue on November 16,2022.

Summary of Utilisation of Proceeds of Rights issue

Particulars	Amount Rs.In lakhs
Amount Raised through Rights Issue of Shares	39,980.18
Less: Rights Issue Expenses	(280.00)
Less: Amount Utilised	(37,490.74)
Balance Amount	2,209.44

6) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024. For the period ended December 31, 2024, the employee benefit expense includes a charge of ₹75.37 Lakhs in respect of equity-settled share-based payment transactions, in accordance with Ind AS 102 - 'Share-based Payment'.

7) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : January 24, 2025



For SUVEN LIFE SCIENCES LTD

Venkat Jasti
VENKAT JASTI
Chairman & MD
DIN: 00278028

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter and nine months ended December 31, 2024 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended.

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


DEDEE PYA NALLURI
Partner

M.No. 225106

UDIN: 25225106BM08YI4373



Place: Hyderabad

Date: January 24, 2025

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
CONSOLIDATED FINANCIAL RESULTS**

To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Regulation")

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies

24/01/2025



Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. Nil, and Rs. Nil for the quarter ended and nine months period ended December 31, 2024 and total net loss after tax of Rs. (2,584.48) lakhs and Rs.(8,479.05) Lakhs for the quarter ended and nine months period ended December 31, 2024, and total comprehensive income of Rs. (2,584.48) Lakhs and Rs. (8,479.05) Lakhs for the quarter ended and nine months period ended December 31, 2024 as considered in the Statement. This interim financial information has been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


DEDEE PYA NALLURI
Partner
M.No. 225106
UDIN: 25225106BM08YJ9361



Place: Hyderabad
Date: January 24, 2025

24/01/2025